XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.23.2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Concentration Risk And Geographic Information [Abstract] |
Schedule of Net Product Revenues by Product | The following table disaggregates total Net Product Revenues by product.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Enzyme product revenues: |  |  |  |  |  |  |
VIMIZIM | $ | 177,392 |  |  | $ | 173,206 |  |  | $ | 366,584 |  |  | $ | 356,265 |
NAGLAZYME | 90,103 |  |  | 115,783 |  |  | 213,124 |  |  | 243,814 |
PALYNZIQ | 74,868 |  |  | 61,643 |  |  | 137,220 |  |  | 116,528 |
ALDURAZYME | 40,318 |  |  | 37,327 |  |  | 74,721 |  |  | 61,709 |
BRINEURA | 38,058 |  |  | 37,725 |  |  | 77,202 |  |  | 73,898 |
Total enzyme product revenues | 420,739 |  |  | 425,684 |  |  | 868,851 |  |  | 852,214 |
VOXZOGO | 113,337 |  |  | 34,374 |  |  | 201,173 |  |  | 54,032 |
KUVAN | 50,622 |  |  | 57,602 |  |  | 101,100 |  |  | 116,939 |
Total net product revenues | 584,698 |  |  | 517,660 |  |  | 1,171,124 |  |  | 1,023,185 |
Royalty and other revenues | 10,577 |  |  | 16,138 |  |  | 20,566 |  |  | 29,972 |
Total revenues | $ | 595,275 |  |  | $ | 533,798 |  |  | $ | 1,191,690 |  |  | $ | 1,053,157 |
Schedule of Total Net Product Revenues Based on Patient Location | The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
United States | $ | 191,655 |  |  | $ | 169,838 |  |  | $ | 358,439 |  |  | $ | 320,653 |
Europe | 183,434 |  |  | 161,231 |  |  | 344,126 |  |  | 318,062 |
Latin America | 75,444 |  |  | 89,911 |  |  | 143,192 |  |  | 152,455 |
Middle East | 25,630 |  |  | 21,414 |  |  | 117,272 |  |  | 87,021 |
Rest of world | 68,217 |  |  | 37,939 |  |  | 133,374 |  |  | 83,285 |
Total net product revenues marketed by the Company | $ | 544,380 |  |  | $ | 480,333 |  |  | $ | 1,096,403 |  |  | $ | 961,476 |
ALDURAZYME net product revenues marketed by Sanofi | 40,318 |  |  | 37,327 |  |  | 74,721 |  |  | 61,709 |
Total net product revenues | $ | 584,698 |  |  | $ | 517,660 |  |  | $ | 1,171,124 |  |  | $ | 1,023,185 |
Schedule of Net Product Revenue Concentrations Attributed to Largest Customers | The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Customer A | 15 | % |  | 16 | % |  | 15 | % |  | 16 | %
Customer B | 12 | % |  | 12 | % |  | 11 | % |  | 12 | %
Customer C | 10 | % |  | 9 | % |  | 9 | % |  | 8 | %
Total | 37 | % |  | 37 | % |  | 35 | % |  | 36 | %

X
- Definition Concentration risk and geographic information. + References No definition available. + Details
Name: | bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix: | bmrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration